Dr. Mark Marzinke is Professor of Pathology and Medicine at the Johns Hopkins University School of Medicine and Co-Principal Investigator of the HPTN Laboratory Center. He is a board-certified clinical chemist and is CLIA Director of the Clinical Pharmacology Analytical Laboratory at Johns Hopkins. He is also Director of the Main Chemistry Laboratory at the Johns Hopkins Hospital. He is the Director of the Clinical Laboratory Core for the Johns Hopkins Center for AIDS Research and Co-Director of Johns Hopkins Tuberculosis Research Advancement Center’s Pharmacology and Pharmacometrics Core. His primary research interests are in the areas of anti-infective pharmacology, HIV prevention science, mass spectrometry, and pharmacogenetics and precision medicine. He provided pharmacology support to the clinical trials that led to the regulatory approval of the dapivirine intravaginal ring and long-acting cabotegravir for HIV prevention. He has served as Principal Investigator, Core Leader, or Co-Investigator on numerous grants. He has published more than 225 peer-reviewed articles, and has held leadership roles in a number of professional organizations.
